FDA Approves Anti-Epileptic Drug XCOPRI

December 5, 2019

FDA Approves Anti-Epileptic Drug XCOPRI

The FDA granted approval to SK Biopharmaceuticals, Co., Ltd. and its U.S. subsidiary SK Life Science, Inc. for XCOPRI (cenobamate tablets) as a treatment for partial-onset seizures in adult patients.This approval is the first time that a Korean pharmaceutical company has independently brought a compound from discovery to U.S. FDA approval. WIth our global footprint, Yourway is well positioned to support international clinical trials.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Pharma Supply Chain & Logistics Innovation Programme EU

May 20-21, 2026
Basel, Switzerland

Schedule a Meeting

Clinical Trial Supply West Coast

September 22-23, 2026
Burlingame, CA

Schedule a Meeting

Media

Articles

Maintaining Temperature Integrity in Direct-to-Patient Clinical Trials

Open chat

Hello! How can I help you?